Administration of intravenous fluids to maintain or expand intravascular volume is one of the common interventions in pre-hospital and hospital medicine. Despite the widespread use of fluids, especially in intensive care patients, there is ongoing controversy over the type of fluid that should be given 1 . Available data suggest that there is wide variation in the type of fluids clinicians use. In a survey of more than 2400 doctors in European countries, 65% of clinicians reported using a mixture of crystalloids and colloids for volume resuscitation, isotonic crystalloids, hydroxy-ethyl starches (HES) and gelatins being the most common fluids used 2 . In contrast, in a survey of 364 clinicians in the Canadian province of Ontario in 1998 to 1999, respondents used predominantly crystalloids for volume expansion; albumin was the most commonly used colloid 3 . Other surveys confirm significant practice variations and suggest that uncertainty over the choice of fluids remains widespread 4, 5 .
Little is known about the reasons for heterogeneity in regard to the choice of fluids for intravascular volume expansion. Factors reported to influence the choice of intravenous fluid include local policies, costs, marketing pressure and published evidence on beneficial or deleterious effects of a specific fluid type 2, 3 . As most data on choice of fluids originate from surveys or point-prevalence studies, it is difficult to assess if these factors have resulted in a change of practice over time.
Human albumin has often been at the heart of the debate on use of different intravenous fluid solutions 6, 7 . In 1998, the Cochrane Injuries Group Albumin Reviewers published a meta-analysis of 30 
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Over the last ten years more reliable information regarding the risks and benefits of the use of albumin for fluid resuscitation has emerged. To determine what influence this has had on clinical practice, we sought to document albumin use (from mass of albumin supplied to hospitals) in 16 industrialised countries between 1995 and 2006. Data on national albumin and synthetic colloid use was sought from independent intensive care researchers and albumin issuers. The mass of albumin supplied per 10,000 persons on an annual basis by country and aggregated across the study countries was calculated. Volumes of synthetic colloid supplied per 10,000 persons were calculated. Data were obtained for 15 countries. Albumin use varied significantly between countries and throughout the observation period. Overall, aggregate albumin use decreased from a peak of 2.54 kg per 10,000 persons in 1995 to 1.40 kg per 10,000 persons in 1999; use has remained relatively constant since. Data on supply of synthetic colloids was available in only three countries and varied from 11.7 litres per 10,000 persons in Canada in 1995, to 231.8 litres per 10,000 persons in Denmark in 2004 . Between 1995 albumin use decreased and has been materially constant since; where data were available, use of synthetic colloids increased. Whether these practice changes have resulted in a net health gain or in harm requires further research. randomised controlled trials involving 1419 patients to quantify the effect of fluids containing human albumin on mortality in critically ill patients with hypovolaemia, burns or hypoproteinaemia 8 . The investigators included trials in adults, children and neonates and concluded that administration of albumin-containing fluids resulted in a 6% absolute increase in the risk of death 8 . In May 2004, the Saline versus Albumin Fluid Evaluation (SAFE) Study investigators reported the first large-scale randomised controlled trial to examine the effect of type of resuscitation fluid on mortality 9 . The study, involving 6997 critically ill adult patients, found that use of either 4% albumin or normal saline for fluid resuscitation resulted in similar 28-day mortality. However, the SAFE investigators and an accompanying editorial noted that further study was needed to determine whether albumin or saline conferred benefit in certain sub-populations of critically ill patients 1, 9 . Subsequently, the same investigators have confirmed that resuscitation with albumin increased mortality in patients with traumatic brain injury 10 . Immediately following the 1998 meta-analysis, albumin use in England, Wales, Scotland and Northern Ireland fell by at least 40% 11 : whether the publication had a similar effect in other parts of the world is not known.
In recent years the suggestion has emerged that the choice of resuscitation fluid and especially the use of HES might increase the risk of renal failure, particularly in patients with severe sepsis. An increased incidence of renal failure and oliguria in intensive care unit patients with severe sepsis and septic shock who received HES as resuscitation fluid was reported by Schortgen et al in 2001 12 . In the following years the association between occurrence of renal failure and use of a specific fluid has been debated 13, 14 . Recently, Brunkhorst and colleagues reported that fluid resuscitation with HES increased the incidence of acute renal failure when compared with fluid resuscitation with modified Ringers lactate solution 15 .
Given the central role of albumin in this controversy, we sought to determine trends in the use of albumin in a number of countries during the last decade and where possible we report trends in synthetic colloid use for comparison.
MATERIALS AND METHODS

Data sources for albumin use
Data on the annual albumin use between 1995 and 2006 were collected from 13 sources representing 15 countries (Australia, Canada, Denmark, England and Wales, Finland, France, Germany, Iceland, New Zealand, Norway, Scotland and Northern Ireland, Sweden and Switzerland). These sources were able to supply data on the amount of albumin issued to hospitals and we make the assumption that any difference between the amounts of albumin supplied to hospitals and the amounts administered to patients is minimal. Data from Australia, New Zealand and Canada were provided by the respective national blood services (Australian Red Cross Blood Service, New Zealand Blood Service and Canadian Blood Service). In Europe, data for Denmark were obtained from Laegemiddelstyrelse (the Danish Drug Administration Agency); for England and Wales combined from BPL Limited; for Finland from the National Registry of Drug Use; for France from the Groupement pour l'élaboration et la réalisation des statistiques; for Germany from the Paul Ehrlich Institute; for Iceland from the Icelandic Medicines Control Agency; for Norway from Octapharm; for Scotland and Northern Ireland combined from the Scottish Blood Transfusion Service; for Sweden from the Apoteket (Swedish Drug Administration Agency); and for Switzerland from the Swiss Agency for Therapeutic Products and from individual companies licensed to supply albumin in Switzerland. We also approached USAbased authors of investigator-initiated studies in the field of resuscitation fluid to seek data on national albumin use in the USA.
Albumin use by country
Information on annual albumin use was provided either by number of units and concentration (4%, 5%, 20% or 25%) or by total amount in kilograms. Annual data on the total amount of albumin used by jurisdiction was standardised by converting all data to kilograms of albumin used per year. For comparison of infusion volumes of albumin and synthetic colloids, volume of synthetic colloid was converted to "5% albumin equivalents" based on published intravascular volume expansion properties [16] [17] [18] . We also documented whether data were provided by calendar year or financial year. In the latter case, data are shown by year-end to represent completed use (for example, for the financial year 2000/2001, total is shown in 2001).
Data sources for synthetic colloid use
Data Canada (Canadian Blood Service), whereas in other countries reliable sources could not be identified.
Synthetic colloid use by country
Information on annual use of synthetic colloids was provided by number of units and concentration. Annual data on the total amount of synthetic colloids used was standardised by converting all data to kilograms of dry weight colloid used per year. Due to the different intravascular volume expansion properties of specific fluids, volume equivalents to the intravascular volume expansion of 5% albumin were calculated (referred to as albumin volume equivalents). According to published data we defined the volume expansion of 5% albumin to be equivalent to 6% HES or 4% gelatin solution, whereas for 6% dextran a conversion factor of 1.2 was assumed 16, [19] [20] [21] [22] . Data provided by financial year are shown by year-end to represent completed use.
Population sources
National population statistics were obtained from the country-specific statistics bureaus using data from census years [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . For non-census years, population totals were calculated assuming linear growth (or decline).
Analysis
Total albumin use in kilograms per 10,000 persons per annum was calculated and plotted to document trends in albumin use over time and between jurisdictions. An aggregate figure was calculated for the years 1995 to 2006 across the surveyed countries for which annual data were available. The mass of synthetic colloids per 10,000 persons per annum were calculated, converted to albumin equivalent volumes and plotted over time. The use of albumin and synthetic colloids was standardised to albumin volume equivalents and plotted over time to document trends in total colloid use in the jurisdictions for which data were available. As data were not available for every year in some jurisdictions, we report only the available data and make no assumptions about missing data.
RESULTS
Availability of information on albumin use
Data on annual albumin use were obtained from 13 sources representing 15 countries. Data were provided by calendar year by 11 countries and by financial year for the remaining four countries. Data were incomplete for England and Wales (missing 1995, 1997, 1998 and 2000) , Germany (missing 1995 to 1998) and Denmark (missing 1995 Denmark (missing to 1996 Denmark (missing and 2006 ). An additional four countries were missing data on 2006 (data not yet available: New Zealand, Norway, Sweden and Switzerland) and four additional countries were missing data for 1995 (Australia, Scotland and Northern Ireland and Sweden). There was no central, national data source for albumin use for the USA and we were unable to identify an alternative reliable data source. Albumin use between 1995 and 2006 Data on albumin use (kg/10,000 persons) in the individual surveyed countries and the aggregate of the surveyed countries are shown in Table 1 and Figures 1 to 4 . The highest national albumin use in any one year was 3.92 kg per 10,000 persons in 1995 in Switzerland, the lowest was 0.43 kg per 10,000 persons in New Zealand in 2005. The aggregate of albumin use in the surveyed countries was decreasing prior to the Cochrane Injuries Group publication in 1998 and decreased further between 1998 and 1999. Since 1999, changes in albumin use in the surveyed countries have generally been less marked. In some countries use has increased (e.g. Australia); in others use has been steady (e.g. New Zealand) or declined (e.g. Germany).
The aggregate use in the surveyed countries decreased from a peak of 2.54 kg per 10,000 persons in 1995 to 1.40 kg per 10,000 persons in 1999. Aggregate albumin use has remained relatively constant since that time, varying between 1.35 kg per 10,000 persons in 2004 and 1.51 kg per 10,000 persons in 2000 (Figures 1 to 4) .
Use of synthetic colloids between 1995 and 2006
Data on synthetic colloids was available for Denmark (1997 to 2005), Sweden (1996 to 2005) and Canada (1995 to 2004). In Denmark HES was the most commonly used synthetic colloid, followed by dextran; use of both colloids increased throughout the observation period. In Sweden, dextran was initially the most frequently used colloid with a decline in use throughout the observation period, whereas HES use increased. In Canada HES use increased throughout the observation period. Data on use of individual synthetic colloids in the surveyed countries are shown in Table 2 and Figure 5 . 
Total use of colloids between 1995 and 2006
Use of synthetic colloids in albumin volume equivalents increased from 125.5 to 195.1 litres per 10,000 population in Denmark (1997 Denmark ( to 2005 , from 127.0 to 188.9 litres per 10,000 population in Sweden (1996 to 2005) and from 11.7 to 71.6 litres per 10,000 population in Canada (1996 to 2004) . The total use of colloids (albumin plus synthetic colloids) showed a trend to increase on a per capita basis in the countries for which data were available ( Figure 6 ).
DISCUSSION
Summary of study findings
We conducted an international study to document annual use of albumin and synthetic colloids in a number of industrialised countries between 1995 and 2006. We found that reliable information on colloid use was difficult to obtain and data were not available for all countries or all years; per capita albumin use varied up to nine-fold between the surveyed countries over time. Synthetic colloid use varied significantly in type and total volume in the few countries for which data were available. Total colloid use (albumin plus synthetic colloids) per capita increased throughout the observation period.
Possible mechanism and comparison with previous studies
We found up to a nine-fold difference in adjusted albumin use between the countries surveyed over time. Although our study cannot explain this variation, possible explanations include differences in the cost of albumin and differences in the availability of alternative fluids in the countries studied. We are unaware of variation in patient demographics between the surveyed countries that might account for the observed variation in albumin use. We have presented the data on a per capita basis using the total population of each country as the denominator. It is possible that differences in the organisation of health care systems and differences in hospitalisation rates between countries may also affect the use of resuscitation fluids.
In 1998, the Cochrane Injuries Group Albumin Reviewers concluded that administration of albumin-containing fluids resulted in a 6% absolute increase in the risk of death 8 . A subsequent survey of clinical directors revealed that in many intensive care units in the United Kingdom use of intravenous albumin had been influenced by this review 36 . In the present study, we found that albumin use in the surveyed countries was decreasing prior to the publication, but we had insufficient data to conduct time-series analysis to determine whether the publication had a material effect on the trend in albumin use 37 .
In contrast to albumin use, use of synthetic colloid increased during the study period. When calculated as volume equivalents, the total volume of albumin and synthetic colloids has remained stable or even increased throughout the observation period. These data do not suggest that clinicians have changed from using colloid solutions to using crystalloids, even though colloids are generally more expensive and meta-analyses report no outcome advantage with colloids [38] [39] [40] .
We are unaware of any previous study examining the use of colloids across a decade in multiple countries. Two surveys have reported clinicians' preferences in choice of resuscitation fluids 2, 3 . These studies suggested that most doctors use a combination of crystalloids and colloids to expand plasma volume: in 1998 to 1999, albumin was the most common colloid used in Canada 3 , whereas in 2001 to 2002, albumin was used infrequently in most European countries 2 .
Study strengths and limitations
Our study is international and may be original in documenting changes in colloid use over a tenyear period in individual countries. However, it has several limitations. First, data were collected retrospectively, obtained for 15 countries only and were incomplete for some years. Second, we found it difficult to obtain comprehensive and reliable data on colloid use. Data were available from national blood bank authorities for only five countries. In the remainder, we sourced data from commercial entities, drug administration agencies and pharmacy registries. Data on synthetic colloids was only available for three countries. We found that commercial organisations were less willing or unable to release data because of commercial sensitivity or because of inadequate data storage and retrieval systems. Also, data sources have become more fragmented over time due to the privatisation of national blood services and replacement of monopolies by competing suppliers. Finally, we have reported total albumin use for each of the surveyed countries and have no information on the proportion of albumin used for the treatment of different groups of patients or for particular indications.
Implications for clinicians and policy makers
Administration of intravenous fluid is one of the most common interventions in pre-hospital and hospital medicine. Accordingly, small differences in outcomes and relative costs which result from the use of different fluid preparations may have important consequences. Although we documented a reduction in albumin use and increased synthetic colloid use in those countries for which data were available, we can only speculate that synthetic colloids are being used in place of albumin. Our data suggest that many clinicians continue to use colloid based resuscitation 2 , and as synthetic colloids may have adverse effects 12 , we do not know whether reduced albumin use has resulted in a net benefit to patients or in harm.
Unanswered questions and future research
Future research should document current fluid resuscitation practices internationally and examine the effects of choice of resuscitation fluid on patient outcomes. Given the widespread use of resuscitation fluids in pre-hospital and hospital medicine, further large-scale international observational studies and randomised controlled trials are warranted. We would like to thank Patrick Robert and Keith Berman of The Marketing Research Bureau, Inc., Orange, CT 06477, USA for supplying the data on worldwide albumin use and for assistance in verifying some country-specific data.
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